相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway
Zhenhong Ni et al.
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737
Mariana Boiani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
BH3 Mimetics: Status of the Field and New Developments
Christian Billard
MOLECULAR CANCER THERAPEUTICS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells
Ricardo Parrondo et al.
PEERJ (2013)
BH3-only proteins in apoptosis at a glance
Lina Happo et al.
JOURNAL OF CELL SCIENCE (2012)
Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics
Jean-Claude Martinou et al.
DEVELOPMENTAL CELL (2011)
Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases
Andreas Strasser et al.
EMBO JOURNAL (2011)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells
O. Kutuk et al.
CELL DEATH AND DIFFERENTIATION (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Mitochondria and cell death: outer membrane permeabilization and beyond
Stephen W. G. Tait et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Min H. Kang et al.
CLINICAL CANCER RESEARCH (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737
Ozgur Kutuk et al.
CANCER RESEARCH (2008)
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models
Alex R. Shoemaker et al.
CLINICAL CANCER RESEARCH (2008)
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Anthony G. Letai
NATURE REVIEWS CANCER (2008)
Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment
Katja Janssen et al.
BLOOD (2007)
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
Jing Deng et al.
CANCER CELL (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Mitochondrial membrane permeabilization in cell death
Guido Kroemer et al.
PHYSIOLOGICAL REVIEWS (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak
Carolina Castilla et al.
ENDOCRINOLOGY (2006)
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (AsP26Glu) and less stable microtubules
M Hari et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Microtubule targeting agents: Basic mechanisms of multidrug resistance (MDR)
AT Fojo et al.
SEMINARS IN ONCOLOGY (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics
A Gonçalves et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
P Giannakakou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
